Skip to Main Content

Paper Details

Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Neuro Oncol
41
2021
COL20A1, DIPGs, DMG, DMGs, Diffuse midline gliomas, H3, HDAC, HDACi, K27M, Quisinostat, RNA, TNNT1, brain tumor, collagen type 20 alpha 1 chain, diffuse intrinsic pontine gliomas, diffuse midline glioma, histone, panobinostat, quisinostat, romidepsin, troponin T1 slow skeletal type, tumor
Author NameAffiliation
Nicholas A VitanzaFred Hutchinson Cancer Research Center
Nicholas A VitanzaSeattle Children's Hospital, University of Washington
Sarah E S LearyFred Hutchinson Cancer Research Center
Sarah E S LearySeattle Children's Hospital, University of Washington
Sabine MuellerUniversity Children's Hospital Zurich
Sabine MuellerUniversity of California San Francisco
Sabine MuellerUniversity Children's Hospital Zurich
Sabine MuellerUniversity of California San Francisco
Javad NazarianUniversity Children's Hospital Zurich
Javad NazarianChildren's National Medical Center
Javad NazarianUniversity Children's Hospital Zurich
Javad NazarianChildren's National Medical Center
Raphael GottardoFred Hutchinson Cancer Research Center
Raphael GottardoUniversity of Washington
Raphael GottardoFred Hutchinson Cancer Research Center
Raphael GottardoFred Hutchinson Cancer Research Center
Raphael GottardoFred Hutchinson Cancer Research Center
Raphael GottardoUniversity of Washington
Mi-Youn BrusniakFred Hutchinson Cancer Research Center
James M OlsonFred Hutchinson Cancer Research Center
James M OlsonSeattle Children's Hospital, University of Washington
  • 1 - 21

Datasets

Release 1.2